Avinash S Patil1, Geeta K Swamy2, Amy P Murtha2, R Phillips Heine2, Xiaomei Zheng3, Chad A Grotegut2. 1. Department of Obstetrics & Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA avi.s.patil@gmail.com. 2. Department of Obstetrics & Gynecology, Duke University Medical Center, Durham, NC, USA. 3. Department of Obstetrics & Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract
OBJECTIVE: We seek to characterize the effect of progesterone metabolites on spontaneous and oxytocin-induced uterine contractility. STUDY DESIGN: Spontaneous contractility was studied in mouse uterine horns after treatment with progesterone, 2α-hydroxyprogesterone, 6β-hydroxyprogesterone (6β-OHP), 16α-hydroxyprogesterone (16α-OHP), or 17-hydroxyprogesterone caproate (17-OHPC) at 10(-9) to 10(-6) mol/L. Uterine horns were exposed to progestins (10(-6) mol/L), followed by increasing concentrations of oxytocin (1-100 nmol/L) to study oxytocin-induced contractility. Contraction parameters were compared for each progestin and matched vehicle control using repeated measures 2-way analysis of variance. In vitro metabolism of progesterone by recombinant cytochrome P450 3A (CYP3A) microsomes (3A5, 3A5, and 3A7) identified major metabolites. RESULTS: Oxytocin-induced contractile frequency was decreased by 16α-OHP (P = .03) and increased by 6β-OHP (P = .05). Progesterone and 17-OHPC decreased oxytocin-induced contractile force (P = .02 and P = .04, respectively) and frequency (P = .02 and P = .03, respectively). Only progesterone decreased spontaneous contractile force (P = .02). Production of 16α-OHP and 6β-OHP metabolites were confirmed in all CYP3A isoforms tested. CONCLUSION: Progesterone metabolites produced by maternal or fetal CYP3A enzymes influence uterine contractility.
OBJECTIVE: We seek to characterize the effect of progesterone metabolites on spontaneous and oxytocin-induced uterine contractility. STUDY DESIGN: Spontaneous contractility was studied in mouse uterine horns after treatment with progesterone, 2α-hydroxyprogesterone, 6β-hydroxyprogesterone (6β-OHP), 16α-hydroxyprogesterone (16α-OHP), or 17-hydroxyprogesterone caproate (17-OHPC) at 10(-9) to 10(-6) mol/L. Uterine horns were exposed to progestins (10(-6) mol/L), followed by increasing concentrations of oxytocin (1-100 nmol/L) to study oxytocin-induced contractility. Contraction parameters were compared for each progestin and matched vehicle control using repeated measures 2-way analysis of variance. In vitro metabolism of progesterone by recombinant cytochrome P450 3A (CYP3A) microsomes (3A5, 3A5, and 3A7) identified major metabolites. RESULTS: Oxytocin-induced contractile frequency was decreased by 16α-OHP (P = .03) and increased by 6β-OHP (P = .05). Progesterone and 17-OHPC decreased oxytocin-induced contractile force (P = .02 and P = .04, respectively) and frequency (P = .02 and P = .03, respectively). Only progesterone decreased spontaneous contractile force (P = .02). Production of 16α-OHP and 6β-OHP metabolites were confirmed in all CYP3A isoforms tested. CONCLUSION:Progesterone metabolites produced by maternal or fetal CYP3A enzymes influence uterine contractility.
Authors: Chad A Grotegut; Liping Feng; Lan Mao; R Phillips Heine; Amy P Murtha; Howard A Rockman Journal: Am J Physiol Endocrinol Metab Date: 2010-12-07 Impact factor: 4.310
Authors: Nicole K Ruddock; Shao-Qing Shi; Sangeeta Jain; Gradie Moore; Gary D V Hankins; Roberto Romero; Robert E Garfield Journal: Am J Obstet Gynecol Date: 2008-10 Impact factor: 8.661
Authors: Roberto Romero; Adi L Tarca; Piya Chaemsaithong; Jezid Miranda; Tinnakorn Chaiworapongsa; Hui Jia; Sonia S Hassan; Cynthia A Kalita; Juan Cai; Lami Yeo; Leonard Lipovich Journal: J Matern Fetal Neonatal Med Date: 2014-01-13